The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. BioSpecifics Technologies is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BSTC and the rest of the Medical group's stocks.
BioSpecifics Technologies is a member of the Medical sector. This group includes 841 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BSTC is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BSTC's full-year earnings has moved 16.81% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, BSTC has moved about 6.06% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.21%. This means that BioSpecifics Technologies is outperforming the sector as a whole this year.
Looking more specifically, BSTC belongs to the Medical - Drugs industry, which includes 179 individual stocks and currently sits at #89 in the Zacks Industry Rank. On average, stocks in this group have gained 9.70% this year, meaning that BSTC is slightly underperforming its industry in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on BSTC as it attempts to continue its solid performance.
Image: Bigstock
Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. BioSpecifics Technologies is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BSTC and the rest of the Medical group's stocks.
BioSpecifics Technologies is a member of the Medical sector. This group includes 841 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BSTC is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BSTC's full-year earnings has moved 16.81% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, BSTC has moved about 6.06% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.21%. This means that BioSpecifics Technologies is outperforming the sector as a whole this year.
Looking more specifically, BSTC belongs to the Medical - Drugs industry, which includes 179 individual stocks and currently sits at #89 in the Zacks Industry Rank. On average, stocks in this group have gained 9.70% this year, meaning that BSTC is slightly underperforming its industry in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on BSTC as it attempts to continue its solid performance.